Aspergillosis,
Scedosporium and
Fusarium, other moulds

^aInitial oral maintenance dose of 200 mg Q 12 hrs is recommended rather than 300 mg Q 12 hrs for considerations of hepatic safety
^bProvision is made for dose increase if inadequate response; 300 mg PO BID (if < 40 kg: 150 mg PO BID); if not tolerating therapy IV dose may be decreased to 3 mg/kg IV Q 12 hrs
^cMaintenance dose may need to be decreased by 50% for patients with mild-to-moderate hepatic impairment (Child-Pugh class A or B), not enough data to recommend in patients with severe hepatic impairment (Child-Pugh class C)
^dNot a FDA-approved indication